Published in Lab Business Week, March 25th, 2007
The guidelines recognize that accurate identification of breast cancers overexpressing HER-2 is critical for identifying patients most likely to respond to agents that target HER-2, such as trastuzumab-based therapy (Herceptin(R)), while minimizing the potential impact of serious treatment-associated side effects.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week